Omalizumab beyond asthma
ABSTRACT: Introduction: Omalizumab has been demonstrated to be a successful therapy in the management of asthma through reduction of patient’s symptoms and use of inhaled corticosteroids. The effect of omalizumab is achieved by immunoglobulin E (IgE) blockage and other secondary mechanisms resulting...
- Autores:
-
Sánchez Caraballo, Jorge Mario
Ramírez Giraldo, Ruth Helena
Diez Zuluaga, Libia Susana
Sus Carrizosa, Sara
Echenique, Alejandro
Olivares Gómez, María Margarita
Cardona Villa, Ricardo
- Tipo de recurso:
- Review article
- Fecha de publicación:
- 2012
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/21273
- Acceso en línea:
- http://hdl.handle.net/10495/21273
- Palabra clave:
- Alergia e Inmunología
Allergy and Immunology
Anafilaxia
Anaphylaxis
Eccema
Eczema
Dermatitis Atópica
Dermatitis, Atopic
Eosinofilia
Eosinophilia
Omalizumab
Mastocitosis
Mastocytosis
Urticaria
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by-nc-nd/2.5/co/
id |
UDEA2_5a5e2ad5ae7d4b6ee485bb9abeb20cbe |
---|---|
oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/21273 |
network_acronym_str |
UDEA2 |
network_name_str |
Repositorio UdeA |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Omalizumab beyond asthma |
title |
Omalizumab beyond asthma |
spellingShingle |
Omalizumab beyond asthma Alergia e Inmunología Allergy and Immunology Anafilaxia Anaphylaxis Eccema Eczema Dermatitis Atópica Dermatitis, Atopic Eosinofilia Eosinophilia Omalizumab Mastocitosis Mastocytosis Urticaria |
title_short |
Omalizumab beyond asthma |
title_full |
Omalizumab beyond asthma |
title_fullStr |
Omalizumab beyond asthma |
title_full_unstemmed |
Omalizumab beyond asthma |
title_sort |
Omalizumab beyond asthma |
dc.creator.fl_str_mv |
Sánchez Caraballo, Jorge Mario Ramírez Giraldo, Ruth Helena Diez Zuluaga, Libia Susana Sus Carrizosa, Sara Echenique, Alejandro Olivares Gómez, María Margarita Cardona Villa, Ricardo |
dc.contributor.author.none.fl_str_mv |
Sánchez Caraballo, Jorge Mario Ramírez Giraldo, Ruth Helena Diez Zuluaga, Libia Susana Sus Carrizosa, Sara Echenique, Alejandro Olivares Gómez, María Margarita Cardona Villa, Ricardo |
dc.subject.decs.none.fl_str_mv |
Alergia e Inmunología Allergy and Immunology Anafilaxia Anaphylaxis Eccema Eczema Dermatitis Atópica Dermatitis, Atopic Eosinofilia Eosinophilia Omalizumab Mastocitosis Mastocytosis Urticaria |
topic |
Alergia e Inmunología Allergy and Immunology Anafilaxia Anaphylaxis Eccema Eczema Dermatitis Atópica Dermatitis, Atopic Eosinofilia Eosinophilia Omalizumab Mastocitosis Mastocytosis Urticaria |
description |
ABSTRACT: Introduction: Omalizumab has been demonstrated to be a successful therapy in the management of asthma through reduction of patient’s symptoms and use of inhaled corticosteroids. The effect of omalizumab is achieved by immunoglobulin E (IgE) blockage and other secondary mechanisms resulting from this blockage. Because other diseases have an important IgE mediation in their physiopathology, the question arises as to if omalizumab would be useful in the treatment of other IgE-mediated diseases. Objective: We present an overview of the experimental studies and clinical reports evaluating the use of omalizumab in diseases different to asthma including atopic dermatitis, urticaria, eosinophilic gastrointestinal disorders, idiopathic anaphylaxis, latex allergy, hymenoptera venom allergy, and other IgE diseases. Methods: We reviewed the literature using PUBMED, EMBASE, and LILACS for publications which used omalizumab in the treatment of patients with allergic diseases or any other diseases. Complete articles published in English, Spanish or Portuguese were included. Conclusion: There is not enough evidence to support the regular use of omalizumab in IgE diseases other than asthma. However, some experimental and clinical investigations indicate that omalizumab could be a therapeutic option in several allergic diseases like atopic dermatitis, urticaria, and eosinophilic gastrointestinal disorders. More control studies are needed in each IgE disease to evaluate the efficacy and safety of omalizumab in IgE mediated diseases. |
publishDate |
2012 |
dc.date.issued.none.fl_str_mv |
2012 |
dc.date.accessioned.none.fl_str_mv |
2021-07-29T15:16:03Z |
dc.date.available.none.fl_str_mv |
2021-07-29T15:16:03Z |
dc.type.spa.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.hasversion.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_dcae04bc |
dc.type.redcol.spa.fl_str_mv |
https://purl.org/redcol/resource_type/ARTREV |
dc.type.local.spa.fl_str_mv |
Artículo de revisión |
format |
http://purl.org/coar/resource_type/c_dcae04bc |
status_str |
publishedVersion |
dc.identifier.citation.spa.fl_str_mv |
Sánchez J, Ramírez R, Díez S, Sus S, Echenique A, Olivares M, Cardona R. Omalizumab beyond asthma. Allergol Immunopathol (Madr). 2012 Sep-Oct;40(5):306-15. doi: 10.1016/j.aller.2011.09.011. |
dc.identifier.issn.none.fl_str_mv |
0301-0546 |
dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/10495/21273 |
dc.identifier.doi.none.fl_str_mv |
10.1016/j.aller.2011.09.011 |
dc.identifier.eissn.none.fl_str_mv |
1578-1267 |
identifier_str_mv |
Sánchez J, Ramírez R, Díez S, Sus S, Echenique A, Olivares M, Cardona R. Omalizumab beyond asthma. Allergol Immunopathol (Madr). 2012 Sep-Oct;40(5):306-15. doi: 10.1016/j.aller.2011.09.011. 0301-0546 10.1016/j.aller.2011.09.011 1578-1267 |
url |
http://hdl.handle.net/10495/21273 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartofjournalabbrev.spa.fl_str_mv |
Allergol. immunopatol. |
dc.rights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ |
dc.rights.accessrights.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.creativecommons.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/2.5/co/ http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.format.extent.spa.fl_str_mv |
10 |
dc.format.mimetype.spa.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Sociedad Española de Inmunología Clínica y Alergología Pediátrica Elsevier |
dc.publisher.group.spa.fl_str_mv |
Grupo de Alergología Clínica y Experimental (GACE) |
dc.publisher.place.spa.fl_str_mv |
Murcia, España |
institution |
Universidad de Antioquia |
bitstream.url.fl_str_mv |
https://bibliotecadigital.udea.edu.co/bitstream/10495/21273/1/SanchezJorge_2012_OmalizumabBeyondAsthma.pdf https://bibliotecadigital.udea.edu.co/bitstream/10495/21273/2/license_rdf https://bibliotecadigital.udea.edu.co/bitstream/10495/21273/3/license.txt |
bitstream.checksum.fl_str_mv |
29f06879526f8ec56484c374576d0924 b88b088d9957e670ce3b3fbe2eedbc13 8a4605be74aa9ea9d79846c1fba20a33 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Institucional Universidad de Antioquia |
repository.mail.fl_str_mv |
andres.perez@udea.edu.co |
_version_ |
1812173133527908352 |
spelling |
Sánchez Caraballo, Jorge MarioRamírez Giraldo, Ruth HelenaDiez Zuluaga, Libia SusanaSus Carrizosa, SaraEchenique, AlejandroOlivares Gómez, María MargaritaCardona Villa, Ricardo2021-07-29T15:16:03Z2021-07-29T15:16:03Z2012Sánchez J, Ramírez R, Díez S, Sus S, Echenique A, Olivares M, Cardona R. Omalizumab beyond asthma. Allergol Immunopathol (Madr). 2012 Sep-Oct;40(5):306-15. doi: 10.1016/j.aller.2011.09.011.0301-0546http://hdl.handle.net/10495/2127310.1016/j.aller.2011.09.0111578-1267ABSTRACT: Introduction: Omalizumab has been demonstrated to be a successful therapy in the management of asthma through reduction of patient’s symptoms and use of inhaled corticosteroids. The effect of omalizumab is achieved by immunoglobulin E (IgE) blockage and other secondary mechanisms resulting from this blockage. Because other diseases have an important IgE mediation in their physiopathology, the question arises as to if omalizumab would be useful in the treatment of other IgE-mediated diseases. Objective: We present an overview of the experimental studies and clinical reports evaluating the use of omalizumab in diseases different to asthma including atopic dermatitis, urticaria, eosinophilic gastrointestinal disorders, idiopathic anaphylaxis, latex allergy, hymenoptera venom allergy, and other IgE diseases. Methods: We reviewed the literature using PUBMED, EMBASE, and LILACS for publications which used omalizumab in the treatment of patients with allergic diseases or any other diseases. Complete articles published in English, Spanish or Portuguese were included. Conclusion: There is not enough evidence to support the regular use of omalizumab in IgE diseases other than asthma. However, some experimental and clinical investigations indicate that omalizumab could be a therapeutic option in several allergic diseases like atopic dermatitis, urticaria, and eosinophilic gastrointestinal disorders. More control studies are needed in each IgE disease to evaluate the efficacy and safety of omalizumab in IgE mediated diseases.COL005956710application/pdfengSociedad Española de Inmunología Clínica y Alergología PediátricaElsevierGrupo de Alergología Clínica y Experimental (GACE)Murcia, Españainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_dcae04bchttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTREVArtículo de revisiónhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/http://purl.org/coar/access_right/c_abf2https://creativecommons.org/licenses/by-nc-nd/4.0/Omalizumab beyond asthmaAlergia e InmunologíaAllergy and ImmunologyAnafilaxiaAnaphylaxisEccemaEczemaDermatitis AtópicaDermatitis, AtopicEosinofiliaEosinophiliaOmalizumabMastocitosisMastocytosisUrticariaAllergol. immunopatol.Allergologia et Immunopathologia306315405ORIGINALSanchezJorge_2012_OmalizumabBeyondAsthma.pdfSanchezJorge_2012_OmalizumabBeyondAsthma.pdfArtículo de revisiónapplication/pdf295700https://bibliotecadigital.udea.edu.co/bitstream/10495/21273/1/SanchezJorge_2012_OmalizumabBeyondAsthma.pdf29f06879526f8ec56484c374576d0924MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8823https://bibliotecadigital.udea.edu.co/bitstream/10495/21273/2/license_rdfb88b088d9957e670ce3b3fbe2eedbc13MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstream/10495/21273/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD5310495/21273oai:bibliotecadigital.udea.edu.co:10495/212732022-12-27 12:21:41.726Repositorio Institucional Universidad de Antioquiaandres.perez@udea.edu.coTk9URTogUExBQ0UgWU9VUiBPV04gTElDRU5TRSBIRVJFClRoaXMgc2FtcGxlIGxpY2Vuc2UgaXMgcHJvdmlkZWQgZm9yIGluZm9ybWF0aW9uYWwgcHVycG9zZXMgb25seS4KCk5PTi1FWENMVVNJVkUgRElTVFJJQlVUSU9OIExJQ0VOU0UKCkJ5IHNpZ25pbmcgYW5kIHN1Ym1pdHRpbmcgdGhpcyBsaWNlbnNlLCB5b3UgKHRoZSBhdXRob3Iocykgb3IgY29weXJpZ2h0Cm93bmVyKSBncmFudHMgdG8gRFNwYWNlIFVuaXZlcnNpdHkgKERTVSkgdGhlIG5vbi1leGNsdXNpdmUgcmlnaHQgdG8gcmVwcm9kdWNlLAp0cmFuc2xhdGUgKGFzIGRlZmluZWQgYmVsb3cpLCBhbmQvb3IgZGlzdHJpYnV0ZSB5b3VyIHN1Ym1pc3Npb24gKGluY2x1ZGluZwp0aGUgYWJzdHJhY3QpIHdvcmxkd2lkZSBpbiBwcmludCBhbmQgZWxlY3Ryb25pYyBmb3JtYXQgYW5kIGluIGFueSBtZWRpdW0sCmluY2x1ZGluZyBidXQgbm90IGxpbWl0ZWQgdG8gYXVkaW8gb3IgdmlkZW8uCgpZb3UgYWdyZWUgdGhhdCBEU1UgbWF5LCB3aXRob3V0IGNoYW5naW5nIHRoZSBjb250ZW50LCB0cmFuc2xhdGUgdGhlCnN1Ym1pc3Npb24gdG8gYW55IG1lZGl1bSBvciBmb3JtYXQgZm9yIHRoZSBwdXJwb3NlIG9mIHByZXNlcnZhdGlvbi4KCllvdSBhbHNvIGFncmVlIHRoYXQgRFNVIG1heSBrZWVwIG1vcmUgdGhhbiBvbmUgY29weSBvZiB0aGlzIHN1Ym1pc3Npb24gZm9yCnB1cnBvc2VzIG9mIHNlY3VyaXR5LCBiYWNrLXVwIGFuZCBwcmVzZXJ2YXRpb24uCgpZb3UgcmVwcmVzZW50IHRoYXQgdGhlIHN1Ym1pc3Npb24gaXMgeW91ciBvcmlnaW5hbCB3b3JrLCBhbmQgdGhhdCB5b3UgaGF2ZQp0aGUgcmlnaHQgdG8gZ3JhbnQgdGhlIHJpZ2h0cyBjb250YWluZWQgaW4gdGhpcyBsaWNlbnNlLiBZb3UgYWxzbyByZXByZXNlbnQKdGhhdCB5b3VyIHN1Ym1pc3Npb24gZG9lcyBub3QsIHRvIHRoZSBiZXN0IG9mIHlvdXIga25vd2xlZGdlLCBpbmZyaW5nZSB1cG9uCmFueW9uZSdzIGNvcHlyaWdodC4KCklmIHRoZSBzdWJtaXNzaW9uIGNvbnRhaW5zIG1hdGVyaWFsIGZvciB3aGljaCB5b3UgZG8gbm90IGhvbGQgY29weXJpZ2h0LAp5b3UgcmVwcmVzZW50IHRoYXQgeW91IGhhdmUgb2J0YWluZWQgdGhlIHVucmVzdHJpY3RlZCBwZXJtaXNzaW9uIG9mIHRoZQpjb3B5cmlnaHQgb3duZXIgdG8gZ3JhbnQgRFNVIHRoZSByaWdodHMgcmVxdWlyZWQgYnkgdGhpcyBsaWNlbnNlLCBhbmQgdGhhdApzdWNoIHRoaXJkLXBhcnR5IG93bmVkIG1hdGVyaWFsIGlzIGNsZWFybHkgaWRlbnRpZmllZCBhbmQgYWNrbm93bGVkZ2VkCndpdGhpbiB0aGUgdGV4dCBvciBjb250ZW50IG9mIHRoZSBzdWJtaXNzaW9uLgoKSUYgVEhFIFNVQk1JU1NJT04gSVMgQkFTRUQgVVBPTiBXT1JLIFRIQVQgSEFTIEJFRU4gU1BPTlNPUkVEIE9SIFNVUFBPUlRFRApCWSBBTiBBR0VOQ1kgT1IgT1JHQU5JWkFUSU9OIE9USEVSIFRIQU4gRFNVLCBZT1UgUkVQUkVTRU5UIFRIQVQgWU9VIEhBVkUKRlVMRklMTEVEIEFOWSBSSUdIVCBPRiBSRVZJRVcgT1IgT1RIRVIgT0JMSUdBVElPTlMgUkVRVUlSRUQgQlkgU1VDSApDT05UUkFDVCBPUiBBR1JFRU1FTlQuCgpEU1Ugd2lsbCBjbGVhcmx5IGlkZW50aWZ5IHlvdXIgbmFtZShzKSBhcyB0aGUgYXV0aG9yKHMpIG9yIG93bmVyKHMpIG9mIHRoZQpzdWJtaXNzaW9uLCBhbmQgd2lsbCBub3QgbWFrZSBhbnkgYWx0ZXJhdGlvbiwgb3RoZXIgdGhhbiBhcyBhbGxvd2VkIGJ5IHRoaXMKbGljZW5zZSwgdG8geW91ciBzdWJtaXNzaW9uLgo= |